AKT1 and breast cancer: The results showed that BC patients with higher CAG_ scores were more sensitive to the AKT inhibitors VIII and Imatinib, while patients with low CAG_ scores responded better to Crizotinib, Saracatinib, Erlotinib, Dasatinib, Rapamycin, Roscovitine and Shikonin (Figure 9A).